(Oleclumab)Biosimilar Reference Antibody-GS40493 新品

货号：GS40493

Oleclumab (also known as MEDI‑9447) is an investigational, human monoclonal antibody that targets CD73 (ecto‑5′‑nucleotidase, NT5E), a cell‑surface enzyme that converts extracellular AMP into adenosine—a potent immunosuppressive metabolite. By binding to CD73, oleclumab inhibits its enzymatic activity, thereby reducing adenosine accumulation in the tumor microenvironment. This blockade aims to reverse adenosine‑mediated suppression of T‑cell and NK‑cell function, enhancing anti‑tumor immunity. It is being developed as an immuno‑oncology agent for the treatment of advanced solid tumors, often in combination with other therapies such as anti‑PD‑L1 antibodies (e.g., durvalumab) and chemotherapy.